Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Arteriovenous Fistula
Interventions
DRUG

Topical Tranexamic Acid 5% with bacitracin

Selected participants received a fixed amount of tranexamic acid 5 %and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.

OTHER

Topical Tranexamic Acid 25% with bacitracin

Selected participants received a fixed amount of tranexamic acid 25%and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.

Trial Locations (3)

92111

Fresenius Medical Care - Kearny Mesa, San Diego

92123

California Insitute of Renal Research, San Diego

92127

Fresenious Medical Care - Rancho, San Diego

All Listed Sponsors
collaborator

Imprimis Pharmaceuticals, Inc.

INDUSTRY

lead

California Institute of Renal Research

OTHER